Anxiety and anxiety states in gynecological practice: possibilities and tools of pharmacotherapy

September 2, 2020
631
Resume

The issues of identification, diagnosis and treatment of anxiety disorders in gynecological practice are considered. The features and mechanism of action of various anxiolytic drugs used in gynecological practice for the prevention and treatment of anxious, anxiety-phobic, depressive, hypochondriac and other mental disorders are presented in detail. The use of an alternative agent of domestic production — the phytocomplex Anxiomedin® and Sonomedin® — is also substantiated. Each of these agents can be successfully used for mild and moderate anxiety disorders in gynecological patients, accompanied by irritation, emotional lability, feelings of anxiety and fear, low adaptive capacity without the risk of developing impaired concentration (Anxiomedin®), or to normalize the processes of falling asleep and improving sleep quality (Sonomedin®).

Published: 02.09.2020

 

References:

  • Batushkin V.V., Inh R.T. (2016) Moduliatsiia systemy hamma-aminomaslianoi kyslotyy pid vplyvom ekstraktu pasyflory inkarnatu, vidnovlennia pokaznykiv vehetatyvnoi rivnovahy ta harmonizatsiia funktsionuvannia tserebralnykh i pidkirkovykh struktur u khvorykh z arterialnoiu hipertenziieiu zhinochoi stati. Kardyolohyia, 5–6: 1–11.
  • Bulavenko O.B. (2008) Nedostatnist liuteinovoi fazy: klinika, diahnostyka ta likuvannia: Avtoref. dys. … d-ra med. nauk: spets. 14.01.01. «Akusherstvo ta hinekolohiia». DU «IPAH NAMN Ukrainy», Kyiv, 37 s.
  • Burchinskiy S.G. (2001) Sovremennyie snotvornyie sredstva. VIsn. farmakol. farm., 1–2: 27–32.
  • Burchinskiy S.G. (2008) Trevozhnyie rasstroystva v obschemeditsinskoy i nevrologicheskoy praktike: problemyi farmakoterapii. Rats. farmakoter., 4: 43–47.
  • Dyukova G.M. (2001) Kachestvo zhizni zhenschinyi v period klimakteriya. Lech. vrach, 1: 3–6.
  • Katasonov A.B. (2018) Neyrobiologicheskie effektyi teanina i ego vozmozhnoe ispolzovanie v nevrologii i psihiatrii. nevrol. psihiatr., 118(11): 118–124.
  • Kostyuchenko S.I. (2008) Epidemiologiya psihicheskogo zdorovya v Ukraine. NeyroNews, 2: 9–13.
  • Marchenko L.A. (2000) Zheltoe telo. Mehanizmyi formirovaniya i regressa. Ginekol. prakt. vrachey, 5(2): 23–25.
  • Prilepskaya V.N., Mezhevitinova E.A. (2005) Predmenstrualnyiy sindrom. Consilium Medicum. Ginekologiya, 7(4): 28–34.
  • Sidelnikova B.M. (2005) Privyichnaya poterya beremennosti. Moskva, 303.
  • Smulevich A.B. (2016) Psihosomaticheskie rasstroystva (klinika, terapiya, organizatsiya meditsinskoy pomoschi). Psihiat. psihofarmakoter., 12(2): 35–51.
  • Syunyakov T.S., Syunyakov S.A., Dorofeeva O.F. (2011) Mehanizmyi anksiogeneza i terapiya trevogi. Consilium Med., 6: 82–89.
  • Tatarchuk T.F., Kosey N.V., Tutchenko T.N. (2016) Lechenie stress-indutsirovannoy nedostatochnosti lyuteinovoy fazyi. Zdorove zhenschinyi, 3: 18–23.
  • Hitrov N.K., Saltyikov A.B. (2003) Bolezni tsivilizatsii i nozologicheskiy printsip meditsinyi s pozitsiy obschey patologii. Klin. med., 1: 5–11.
  • Chaban O.S., Khaustova O.O. (2020) Tryvoha u patsiientiv ikh khronichnymy neinfektsiinymy zakhvoriuvanniamy: subklinichni ta psykhosomatychni oznaky, diahnostyka, terapiia. NeiroNews, 3: 38–44.
  • Accorti E.E., Wong M.S. (2017) It is time for routine screening for perinatal mood and anxiety disorders in obstetrics and gynecology settings. Obstet. Gynecol. Surv., 72: 553–568.
  • Appleton J.K. (2012) Hypnotics: past, presence, future. Modern Neuropsychopharmacology. Illinois Univ. Press, Chicago, Vol. 4, р. 164–198.
  • Birkhaueser M., Genazzani A.R. (Eds.) (2018) Pre-menopausal, menopause and beyond: vol. 5: Frontiers in gynecological endocrinology. Cham, Springer, 326 p.
  • Bryant C., Kleinstauber M., Judd H. (2014) Aspects of mental health care in the gynecological setting. Women’s Health, 10: 237–254.
  • Burk J.D., Regier D.A. (1994) Epidemiology of mental disorders. Textbook of Psychiatry. Am. Psychiatr. Press, N.Y., р. 67–89.
  • Chandrasekhar K., Kapoor J., Anishetty S. (2012) A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J. Psychol. Med., 34(3): 255–262. doi: 10.4103/0253-7176.106022.
  • Cohen L.S. (2005) Diagnosis and management of mood disorders during the menopausal transition. Am. J. Med.,118: 93S—97S.
  • Cornblatt D.J., Peters A.M., De Souza A. (2004) Use of psychotropic drugs in general practice. Psychiatric Aspects in General Medicine. Illinois Univ. Press, Chicago, р. 235–244.
  • Devoto L. (2000) The human corpus luteum: life cycle and function in natural cycles. Fertil Steril., 02(3): 1067–1070.
  • Freeman E.W., Sondheimer S.J. (2003) Premenstrual dysphoric disorder: recognition and treatment. J. Clin. Psychiat., 5: 30–39.
  • Haskell C.F., Kennedy D.O., Milne A.L. et al. (2008) The effects of L-theanine, caffeine and their combination on cognition and mood. Biol. Psychiat., 77: 113–122.
  • Henderson V.W. (2005) Menopause and disorders of the central nervous system. Minerva Ginecol., 57: 579–592.
  • Hidese S., Ota M., Wakabayashi C. et al. (2017) Effects of chronic L-theanine administration in patients with major depressive disorder: an open-label study. Acta Neuropsychiat., 29: 72–79.
  • Jaysing Salve et al. (2019) Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clin. Study. Cureus, 11(12): e6466. doi: 10.7759/cureus.6466.
  • Kulkarni S.K., Dhir A. (2008) Withania somnifera: an Indian ginseng. Progr. Neuropsychopharmacol Biol. Psychiat., 32: 1093–1105.
  • Kumar A., Kalonia H. (2008) Effect of Withania somnifera on sleep-wake cyclt in sleep-disturbed rats: possible GABA-ergic mechanism. Ind. J. Pharm. Res., 8: 806–812.
  • Leddy M.A., Lawrence H., Schulkin J. (2011) Obstetrician-gynecologists and women’s mental health: findings of the collaborative ambulatory research network 2005–2009. Obstet. Gynecol. Surv., 66: 316–323.
  • Louik C. (2007) First-trimester yse of selective serotonin-reuptake inhibitors and the risk of birth defects. N. Eng. J. Med., 172: 57–59.
  • McCabe S. (2002) Complimentary herbal and alternative drugs in clinical practice. Perspect. Psychiat. Care, 38: 98–107.
  • Miroddi M., Calapai G. et al. (2013) Passiflora incarnate L.: ethnopharmacology, clinical application, safety and evaluation of clinical trials. J. Ethnopharmacol., 150: 791–804.
  • Pratte M.A., Nanavati K.B. (2014) An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb Ashwagandha (Withania somnifera). J. Alternat. Comparat. Med., 20: 901–908.
  • Williams J., Everett J.M., D’Cunha N.M., Sergi D. (2020) The Effects of Green Tea Amino Acid L-Theanine Consumption on the Ability to Manage Stress and Anxiety Levels: a Systematic Review. Plant Foods Hum. Nutr., 75(1): 12–23.